D L Dunner

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression
    David L Dunner
    Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA
    J Clin Psychiatry 67:688-95. 2006
  2. ncbi request reprint Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials
    David L Dunner
    Center for Anxiety and Depression, University of Washington, Seattle, Washington 98105 6099, USA
    Clin Ther 27:1901-11. 2005
  3. ncbi request reprint Safety and tolerability of emerging pharmacological treatments for bipolar disorder
    David L Dunner
    Center for Anxiety and Depression, and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98105, USA
    Bipolar Disord 7:307-25. 2005
  4. ncbi request reprint Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
    J Affect Disord 87:115-9. 2005
  5. ncbi request reprint Atypical antipsychotics: efficacy across bipolar disorder subpopulations
    David L Dunner
    Center for Anxiety and Depression, University of Washington, Seattle, WA 98105 6099, USA
    J Clin Psychiatry 66:20-7. 2005
  6. ncbi request reprint Correlates of suicidal behavior and lithium treatment in bipolar disorder
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105 6099, USA
    J Clin Psychiatry 65:5-10. 2004
  7. ncbi request reprint Dysthymia and double depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Medical School, Washington 98105, USA
    Int Rev Psychiatry 17:3-8. 2005
  8. ncbi request reprint Treatment considerations for depression in the elderly
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA
    CNS Spectr 8:14-9. 2003
  9. ncbi request reprint Drug interactions of lithium and other antimanic/mood-stabilizing medications
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and the Center for Anxiety and Depression, Seattle 98105, USA
    J Clin Psychiatry 64:38-43. 2003
  10. ncbi request reprint Duration of periods of euthymia in patients with dysthymic disorder
    D L Dunner
    Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington, Seattle, USA
    Am J Psychiatry 156:1992-3. 1999

Collaborators

Detail Information

Publications63

  1. ncbi request reprint Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression
    David L Dunner
    Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105, USA
    J Clin Psychiatry 67:688-95. 2006
    ..We report on the characteristics and outcomes of a large cohort of patients with a level of treatment resistance that is very substantial and who were treated for 2 years with standard care...
  2. ncbi request reprint Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials
    David L Dunner
    Center for Anxiety and Depression, University of Washington, Seattle, Washington 98105 6099, USA
    Clin Ther 27:1901-11. 2005
    ..The aims of this work were to assess the efficacy and tolerability of controlled-release paroxetine (paroxetine CR) in the treatment of outpatients with severe major depressive disorder (MDD)...
  3. ncbi request reprint Safety and tolerability of emerging pharmacological treatments for bipolar disorder
    David L Dunner
    Center for Anxiety and Depression, and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98105, USA
    Bipolar Disord 7:307-25. 2005
    ..As the armamentarium for treating BPD increases, it allows for the possibility of choosing drugs on the basis of their tolerability as well as their efficacy, rather than on efficacy alone...
  4. ncbi request reprint Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, 4225 Roosevelt Way NE, Ste 306C, Seattle, WA 98105, United States
    J Affect Disord 87:115-9. 2005
    ..This study investigated the rate of hypomania, mania, and hypomanic-like symptoms observed during treatment with duloxetine in patients with major depression...
  5. ncbi request reprint Atypical antipsychotics: efficacy across bipolar disorder subpopulations
    David L Dunner
    Center for Anxiety and Depression, University of Washington, Seattle, WA 98105 6099, USA
    J Clin Psychiatry 66:20-7. 2005
    ..In addition, they have shown effectiveness and tolerability in small-scale and open-label trials and case studies with pediatric and geriatric bipolar patients...
  6. ncbi request reprint Correlates of suicidal behavior and lithium treatment in bipolar disorder
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105 6099, USA
    J Clin Psychiatry 65:5-10. 2004
    ..Research does tend to agree that lithium is efficacious in decreasing suicidal behavior in patients with affective disorders...
  7. ncbi request reprint Dysthymia and double depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Medical School, Washington 98105, USA
    Int Rev Psychiatry 17:3-8. 2005
    ..This paper renews the diagnostic status of dysthymic disorder, treatment studies, and makes suggestions for the classification of chronic forms of depression for DSM-V...
  8. ncbi request reprint Treatment considerations for depression in the elderly
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA
    CNS Spectr 8:14-9. 2003
    ..This article discusses pharmacotherapeutic and psychotherapeutic approaches to the treatment of depression in the elderly population...
  9. ncbi request reprint Drug interactions of lithium and other antimanic/mood-stabilizing medications
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and the Center for Anxiety and Depression, Seattle 98105, USA
    J Clin Psychiatry 64:38-43. 2003
    ..Successful management of medications for the patient with bipolar disorder is a challenge, but increased effort and vigilance by clinicians mean a reduced risk of hospitalization and fewer office visits for patients...
  10. ncbi request reprint Duration of periods of euthymia in patients with dysthymic disorder
    D L Dunner
    Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington, Seattle, USA
    Am J Psychiatry 156:1992-3. 1999
    ..The purpose of this study was to assess the duration of periods of euthymia in patients with dysthymia...
  11. ncbi request reprint Optimizing lithium treatment
    D L Dunner
    Department of Psychiatry and Behavioral Sciences and the Center for Anxiety and Depression, University of Washington, Seattle, USA
    J Clin Psychiatry 61:76-81. 2000
    ..Since side effects can affect compliance, recognition and treatment of early and late-appearing side effects are important aspects of lithium pharmacotherapy...
  12. ncbi request reprint Acute and maintenance treatment of chronic depression
    D L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98105 6099, USA
    J Clin Psychiatry 62:10-6. 2001
    ..Newer treatments, such as the combination of psychotherapy and pharmacotherapy, may prove to be of greatest benefit for individuals with chronic mood disorders...
  13. ncbi request reprint Management of anxiety disorders: the added challenge of comorbidity
    D L Dunner
    Department of Psychiatry and Behavioral Sciences and Center for Anxiety and Depression, University of Washington, 4225 Roosevelt Way NE, Suite 306 C, Seattle, Washington 98105, USA
    Depress Anxiety 13:57-71. 2001
    ..The impact of co-existing multiple anxiety disorders, depression, or a history of substance abuse will be discussed with a view to choosing the appropriate management strategy. Treatment options will be reviewed...
  14. ncbi request reprint Six-year perspectives on the safety and tolerability of nefazodone
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105 6099, USA
    J Clin Psychiatry 63:32-41. 2002
  15. ncbi request reprint The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders
    John H Lee
    Department of Biology, University of Washington, Seattle, Washington 98040, USA
    Depress Anxiety 25:91-7. 2008
    ..Anxiety disorders negatively impact the course of bipolar disorders. The high prevalence and risk rate of comorbid anxiety disorders in bipolar patients highlight the need for greater clinical attention to this population...
  16. ncbi request reprint Differential subtyping of depression
    T Yang
    Department of Psychiatry and Behavioral Science, Center for Anxiety and Depression, University of Washington, 4225 Roosevelt Way NE, Suite 306C, Seattle, WA 98105-6099, USA
    Depress Anxiety 13:11-7. 2001
    ..However, in the course of reviewing the literature on this topic, very few studies have separated patients into these distinct depressive subtypes. Further studies are needed to indicate if these subtypes can be meaningfully separated...
  17. ncbi request reprint Antidepressant-induced hypomania in treatment-resistant depression
    Cynthia D Bader
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    J Psychiatr Pract 13:233-7. 2007
    ..However, the patients described in the literature have not had treatment-resistant depression...
  18. ncbi request reprint Interactive case conference. First episode: depression and panic disorder
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    CNS Spectr 10:696-7. 2005
  19. ncbi request reprint Clinical consequences of under-recognized bipolar spectrum disorder
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington School of Medicine, Seattle, WA 98105, USA
    Bipolar Disord 5:456-63. 2003
    ..Depressive episodes are common in patients who experience BSDs, and increasingly treatment approaches designed specifically for bipolar depression are being studied...
  20. ncbi request reprint Bipolar disorder not otherwise specified in relation to the bipolar spectrum
    Cynthia D Bader
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    Bipolar Disord 9:860-7. 2007
    ..Our hypothesis was that patients with BPD NOS would be more similar to other bipolar patients than major depressive disorder (MDD) patients in terms of age of onset, history of suicidal behavior and family history of BPD...
  21. ncbi request reprint Duloxetine in treatment of anxiety symptoms associated with depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington Center for Anxiety and Depression, Seattle, WA, USA
    Depress Anxiety 18:53-61. 2003
    ..Efficacy in these three key symptom domains may in turn explain the high probabilities of remission (43-57%) observed in these studies...
  22. ncbi request reprint The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression
    Rachel Manber
    Department of Psychiatry and Behavioral Sciences, Stanford University, CA 94305, USA
    Sleep 26:130-6. 2003
    ..The purpose of the study was to compare the effects of psychotherapy, nefazodone, and their combination on subjective measures of sleep in patients with chronic forms of major depression...
  23. ncbi request reprint A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression
    David H Avery
    Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Harborview Medical Center, Seattle, 98104 2499, USA
    Biol Psychiatry 59:187-94. 2006
    ..Repetitive transcranial magnetic stimulation (TMS) as a treatment for depression has shown statistically significant effects, but the clinical significance of these effects has been questioned...
  24. ncbi request reprint Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, USA
    Depress Anxiety 25:E1-8. 2008
    ..The adverse events causing discontinuation during the extension phase were generally not unique to the extension phase. Few patients experienced significant weight gain...
  25. ncbi request reprint Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled study
    David H Avery
    Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, Seattle, Washington 98104 2499, USA
    J Nerv Ment Dis 195:378-81. 2007
    ..Compared with sham, TMS was associated with a significant (p < 0.05) reduction in the SAFTEE pain item during the study. The reduction in pain could not be explained by the antidepressant effects...
  26. ncbi request reprint Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder
    Seth D Friedman
    Department of Radiology, University of Washington, Seattle, Washington, USA
    Biol Psychiatry 56:340-8. 2004
    ..This study examined whether lithium (Li) and valproic acid (VPA) treatment modulated these chemicals...
  27. ncbi request reprint A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V
    Benjamin J D H Chun
    Department of Psychiatry and Behavioral Science, Center for Anxiety and Depression, University of Washington, Seattle, WA 98105, USA
    Bipolar Disord 6:32-42. 2004
    ..To determine if the classification of 'antidepressant-induced hypomania' in DSM-IV is supported by available data...
  28. ncbi request reprint Interactive case conference. Double depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, Center for Anxiety and Depression, University of Washington, Seattle, USA
    CNS Spectr 10:174. 2005
  29. ncbi request reprint Treatment-resistant bipolar disorder: a comparison of rapid cyclers and nonrapid cyclers
    Dong Vo
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98015, USA
    CNS Spectr 8:948-52. 2003
    ..We investigated clinical factors to determine their relationship to treatment resistance among bipolar patients who had a consultation at a tertiary care facility...
  30. ncbi request reprint Brain metabolic alterations in medication-free patients with bipolar disorder
    Stephen R Dager
    Department of Radiology, University of Washington, Seattle 98105, USA
    Arch Gen Psychiatry 61:450-8. 2004
    ..Bipolar disorder (BD) has substantial morbidity and incompletely understood neurobiological underpinnings...
  31. ncbi request reprint Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination
    Robert M A Hirschfeld
    Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas 77555 0188, USA
    Biol Psychiatry 51:123-33. 2002
    ..This study compared efficacy of nefazodone, psychotherapy, and their combination in improving psychosocial functioning in chronically depressed outpatients...
  32. ncbi request reprint Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    J Clin Psychiatry 68:1071-7. 2007
    ..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...
  33. ncbi request reprint Bipolar depression
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    CNS Spectr 10:528. 2005
  34. ncbi request reprint Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression
    Sona Dimidjian
    Department of Psychology, University of Washington, USA
    J Consult Clin Psychol 74:658-70. 2006
    ..The implications of these findings for the evaluation of current treatment guidelines and dissemination are discussed...
  35. ncbi request reprint Dysthymic disorder: treatment with citalopram
    David L Dunner
    Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA
    Depress Anxiety 15:18-22. 2002
    ..Various criteria for response and remission were employed. These findings are intended to give guidelines for a subsequent treatment study of dysthymic patients with citalopram using a double-blind placebo-controlled strategy...
  36. ncbi request reprint Interactive case conference: depression, dementia, or pseudodementia?
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    CNS Spectr 10:862. 2005
  37. ncbi request reprint Anxiety and depression in the elderly: implications for diagnosis and treatment
    David L Dunner
    Department of Psychiatry, University of Washington, Seattle, Washington, USA
    CNS Spectr 8:5. 2003
  38. ncbi request reprint Interactive case conference: Depression in the elderly
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    CNS Spectr 10:354. 2005
  39. ncbi request reprint Interactive case conference. First onset of schizophrenia
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
    CNS Spectr 11:19. 2006
  40. doi request reprint Rapid cycling bipolar disorder--diagnostic concepts
    Michael Bauer
    Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany
    Bipolar Disord 10:153-62. 2008
    ..This paper reviews the literature to examine the DSM-IV diagnostic criteria for rapid cycling in bipolar disorder...
  41. pmc Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression
    Keith S Dobson
    Department of Psychology, University of Calgary, Calgary, Alberta, Canada
    J Consult Clin Psychol 76:468-77. 2008
    ..These findings suggest that behavioral activation may be nearly as enduring as cognitive therapy and that both psychotherapies are less expensive and longer lasting alternatives to medication in the treatment of depression...
  42. ncbi request reprint Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:582-7. 2007
    ..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
  43. ncbi request reprint A comparison of initial duloxetine dosing strategies in patients with major depressive disorder
    Virgil G Whitmyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:1921-30. 2007
    ..To compare the effects of starting doses of duloxetine taken with or without food on tolerability and efficacy in patients with major depressive disorder (MDD)...
  44. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  45. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  46. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  47. ncbi request reprint Preventing recurrent depression: long-term treatment for major depressive disorder
    Pierre Blier
    Department of Psychiatry, Institute of Mental Health Research, University of Ottawa, Canada
    J Clin Psychiatry 68:e06. 2007
    ..Maintenance therapy considerations for clinicians include assessing treatment guidelines, addressing nonadherent patients, and measuring medication treatment response...
  48. ncbi request reprint Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
    Todd M Sanger
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Affect Disord 73:155-61. 2003
    ..A substantial proportion of patients with bipolar disorder are characterized by a rapidly cycling course and are particularly resistant to conventional treatment...
  49. ncbi request reprint Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
    J Clin Psychiatry 63:493-500. 2002
    ..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances...
  50. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD...
  51. ncbi request reprint Efficacy of controlled-release paroxetine in the treatment of late-life depression
    Mark Hyman Rapaport
    Department of Psychiatry, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, 8730 Alden Dr, Suite C301, Los Angeles, CA 90048, USA
    J Clin Psychiatry 64:1065-74. 2003
    ..Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition...
  52. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  53. ncbi request reprint Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression
    Daniel N Klein
    Department of Psychology, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    J Consult Clin Psychol 72:681-8. 2004
    ..The 2 conditions also differed significantly on change in depressive symptoms over time. These findings support the use of CBASP as a maintenance treatment for chronic forms of MDD...
  54. ncbi request reprint The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
    ..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
  55. ncbi request reprint Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 30:405-16. 2005
    ..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings...
  56. pmc Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322
    Proc Natl Acad Sci U S A 100:14293-6. 2003
    ..Our results suggest that psychotherapy may be an essential element in the treatment of patients with chronic forms of major depression and a history of childhood trauma...
  57. ncbi request reprint Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10021, USA
    Psychopharmacol Bull 37:73-87. 2003
    ..COMB was associated with less symptom re-emergence during the continuation phase than either monotherapy, particularly for partial remitters...
  58. ncbi request reprint Regional cerebral cortical thinning in bipolar disorder
    In Kyoon Lyoo
    McLean Hospital Brain Imaging Center, Harvarrd Medical School, Boston, MA, USA
    Bipolar Disord 8:65-74. 2006
    ..This study was conducted to explore differences in cortical thickness between subjects with bipolar disorder and healthy comparison subjects using cortical surface-based analysis...
  59. ncbi request reprint Basal ganglia shape alterations in bipolar disorder
    Jaeuk Hwang
    Department of Psychiatry, Seoul National University Hospital, 28 Yongon Dong, Chongno Gu, Seoul 110 744, South Korea
    Am J Psychiatry 163:276-85. 2006
    ....
  60. ncbi request reprint Frontal lobe gray matter density decreases in bipolar I disorder
    In Kyoon Lyoo
    Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478, USA
    Biol Psychiatry 55:648-51. 2004
    ..This study was conducted to explore differences in gray and white matter density between bipolar and healthy comparison groups using voxel-based morphometry (VBM)...
  61. ncbi request reprint The occurrence of cavum septi pellucidi enlargement is increased in bipolar disorder patients
    Minue J Kim
    McLean Hospital Brain Imaging Center, Harvard Medical School, Boston, MA, USA
    Bipolar Disord 9:274-80. 2007
    ..This study was conducted to evaluate the prevalence of cavum septi pellucidi (CSP) enlargement in patients with bipolar disorder (BD) and healthy comparison subjects...
  62. doi request reprint Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report
    S Nassir Ghaemi
    Bipolar Disorder Research Program, Department of Psychiatry, Emory University, Atlanta, GA 30322, USA
    Bipolar Disord 10:117-28. 2008
    ....
  63. ncbi request reprint A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn, USA
    J Clin Psychiatry 67:1674-81. 2006
    ..The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in outpatients with major depressive disorder...